EcoDrugPlus

Phosphodiesterase 4a

Ensembl ID : ENSSTOG00000027947
Gene Symbol: PDE4A
3 Cross references
275 Possible Orthologues:

Phosphodiesterase 4b

Ensembl ID : ENSSTOG00000028938
Gene Symbol: PDE4B
3 Cross references
293 Possible Orthologues:

Phosphodiesterase 4c

Ensembl ID : ENSSTOG00000000320
Gene Symbol: PDE4C
2 Cross references
267 Possible Orthologues:

Phosphodiesterase 4d

Ensembl ID : ENSSTOG00000024554
Gene Symbol: PDE4D
3 Cross references
244 Possible Orthologues:

Phosphodiesterase 5a

Ensembl ID : ENSSTOG00000025252
Gene Symbol: PDE5A
4 Cross references
220 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSSTOG00000008795
Gene Symbol: PDE7A
3 Cross references
253 Possible Orthologues:

Phosphodiesterase 7b

Ensembl ID : ENSSTOG00000020095
Gene Symbol: PDE7B
4 Cross references
189 Possible Orthologues:

Phosphodiesterase 9a

Ensembl ID : ENSSTOG00000001452
Gene Symbol: PDE9A
3 Cross references
280 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 1

Ensembl ID : ENSSTOG00000005560
Gene Symbol: PIK3R1
4 Cross references
203 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 2

Ensembl ID : ENSSTOG00000001921
Gene Symbol: PIK3R2
4 Cross references
253 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSSTOG00000006051
Gene Symbol: PIK3R3
4 Cross references
274 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSSTOG00000005231
Gene Symbol: PIK3R5
3 Cross references
255 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).